{"id":"v114","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, swelling, or itching at the injection site"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"This vaccine is designed to stimulate an immune response against the SARS-CoV-2 virus, with the goal of preventing infection and disease. The VSV vector is used to deliver the spike protein to immune cells, where it is processed and recognized as foreign, triggering an immune response.","oneSentence":"V114 is a recombinant vesicular stomatitis virus (VSV) vector-based vaccine that expresses the SARS-CoV-2 spike protein.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:53:55.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19"}]},"trialDetails":[{"nctId":"NCT04193215","phase":"PHASE3","title":"V114 and Acute Otitis Media (V114-032/PNEU-ERA)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-09-12","conditions":"Acute Otitis Media (AOM)","enrollment":7119},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT04633226","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-10","conditions":"Pneumococcal Disease","enrollment":58},{"nctId":"NCT03615482","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 When Administered Concomitantly With Influenza Vaccine in Healthy Adults 50 Years of Age or Older (V114-021/PNEU-FLU)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-14","conditions":"Pneumococcal Infections","enrollment":1200},{"nctId":"NCT03565900","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Allogeneic Hematopoietic Stem Cell Transplant Recipients (V114-022/PNEU-STEM)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-09-12","conditions":"Pneumococcal Infections","enrollment":277},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT03692871","phase":"PHASE3","title":"A Study to Evaluate the Safety and Tolerability of V114 and Prevnar 13™ in Healthy Infants (V114-031/PNEU-LINK)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-12-14","conditions":"Pneumococcal Infections","enrollment":2409},{"nctId":"NCT04384107","phase":"PHASE3","title":"Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-033)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-07-01","conditions":"Pneumococcal Infections","enrollment":694},{"nctId":"NCT04031846","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-025)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-09-04","conditions":"Pneumococcal Infections","enrollment":1184},{"nctId":"NCT03921424","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Children Infected With Human Immunodeficiency Virus (HIV) (V114-030/PNEU-WAY PED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-11-05","conditions":"Pneumococcal Infections","enrollment":407},{"nctId":"NCT04016714","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-08-28","conditions":"Pneumococcal Infections","enrollment":1191},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT03885934","phase":"PHASE3","title":"Safety and Immunogenicity of Catch-up Vaccination Regimens of V114 (V114-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-25","conditions":"Pneumococcal Infections","enrollment":606},{"nctId":"NCT03480802","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults Infected With Human Immunodeficiency Virus (HIV) (V114-018)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-06","conditions":"Pneumococcal Infections","enrollment":302},{"nctId":"NCT03480763","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Healthy Adults 50 Years of Age or Older (V114-016/PNEU-PATH)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-06-22","conditions":"Pneumococcal Infections","enrollment":652},{"nctId":"NCT03731182","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 in Children With Sickle Cell Disease (V114-023/PNEU-SICKLE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-01-23","conditions":"Pneumococcal Infections","enrollment":104},{"nctId":"NCT03950622","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Adults (V114-019/PNEU-AGE)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-13","conditions":"Pneumococcal Infections","enrollment":1205},{"nctId":"NCT03950856","phase":"PHASE3","title":"Lot-to-Lot Consistency of V114 in Healthy Adults (V114-020)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-12","conditions":"Pneumococcal Infections, Pneumonia, Pneumococcal","enrollment":2340},{"nctId":"NCT03547167","phase":"PHASE3","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by PNEUMOVAX™23 in Adults at Increased Risk for Pneumococcal Disease (V114-017/PNEU-DAY)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-07-16","conditions":"Pneumococcal Infections","enrollment":1515},{"nctId":"NCT02987972","phase":"PHASE2","title":"A Study to Evaluate the Safety, Tolerability, and Immunogenicity of Two Lots of V114 in Healthy Infants (V114-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2017-03-21","conditions":"Pneumococcal Infections","enrollment":1051},{"nctId":"NCT02573181","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of V114 Compared to Prevnar 13™ in PPSV23-vaccinated Healthy Adults ≥65 Years of Age (V114-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-30","conditions":"Pneumococcal Infections","enrollment":253},{"nctId":"NCT02037984","phase":"PHASE1, PHASE2","title":"Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-004)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-01-28","conditions":"Streptococcus Pneumoniae Infection, Pneumococcal Infections","enrollment":341},{"nctId":"NCT01215188","phase":"PHASE2","title":"A Study of Pneumococcal Conjugate Vaccine (V114) Compared to a Marketed Vaccine (V114-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2010-10-14","conditions":"Pneumococcal Infections","enrollment":1152},{"nctId":"NCT02547649","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of Two Formulations of V114 in Healthy Adults 50 Years of Age or Older (V114-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-10-08","conditions":"Pneumococcal Infections","enrollment":690},{"nctId":"NCT02531373","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-09-15","conditions":"Pneumococcal Infections","enrollment":338},{"nctId":"NCT01215175","phase":"PHASE1","title":"Safety and Tolerability Study for the Pneumococcal Conjugate Vaccine V114 Versus Prevnar™ (V114-001)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Pneumococcal Infections","enrollment":150},{"nctId":"NCT01513551","phase":"PHASE2","title":"The Safety, Tolerability, and Immunogenicity Profiles of a Single Dose of V114, PNEUMOVAX® 23, or PREVNAR 13® in Adults 50 Years of Age or Older (V114-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2012-03-13","conditions":"Pneumococcal Infections","enrollment":692}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VAXNEUVANCE™","Pneumococcal 15-Valent Conjugate Vaccine","15-Valent Pneumococcal Conjugate","Vaccine","Pneumococcal 15-valent Conjugate Vaccine, VAXNEUVANCE™"],"phase":"phase_3","status":"active","brandName":"V114","genericName":"V114","companyName":"Merck Sharp & Dohme LLC","companyId":"merck-sharp-dohme-llc","modality":"Biologic","firstApprovalDate":"","aiSummary":"V114 is a recombinant vesicular stomatitis virus (VSV) vector-based vaccine that expresses the SARS-CoV-2 spike protein. Used for Prevention of COVID-19.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":20,"withResults":19},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}